MwanzoSNG • LON
add
Synairgen plc
Bei iliyotangulia
GBX 4.71
Bei za siku
GBX 4.37 - GBX 4.75
Bei za mwaka
GBX 3.00 - GBX 10.88
Thamani ya kampuni katika soko
8.93M GBP
Wastani wa hisa zilizouzwa
elfu 162.56
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
LON
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (GBP) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 1.95M | -29.14% |
Mapato halisi | -1.63M | 31.28% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | — | — |
EBITDA | -1.95M | 28.75% |
Asilimia ya kodi ya mapato | 10.92% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (GBP) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 8.59M | -19.19% |
Jumla ya mali | 10.64M | -43.12% |
Jumla ya dhima | 1.08M | -60.69% |
Jumla ya hisa | 9.56M | — |
hisa zilizosalia | 201.37M | — |
Uwiano wa bei na thamani | 0.94 | — |
Faida inayotokana na mali | -45.90% | — |
Faida inayotokana mtaji | -51.07% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (GBP) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -1.63M | 31.28% |
Pesa kutokana na shughuli | -1.84M | 30.36% |
Pesa kutokana na uwekezaji | elfu 882.00 | 88,100.00% |
Pesa kutokana na ufadhili | — | — |
Mabadiliko halisi ya pesa taslimu | elfu -962.50 | 63.64% |
Mtiririko huru wa pesa | -1.13M | 24.89% |
Kuhusu
Synairgen is a University spin-off and public limited company working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna E. Davies and Ratko Djukanovic. The company is developing an inhaled formulation of interferon-beta for severe viral respiratory diseases including COVID-19.
Richard Marsden was appointed chief executive officer in September 2009. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2003
Tovuti
Wafanyakazi
36
